JonesResearch assumed coverage of Precision BioSciences (DTIL) with a Buy rating and $30 price target The firm views the company as an “underappreciated gene editing story.” The price target is based on PBGENE-HBV in hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences receives CTA approval to expand Eliminate-B trial
- Precision BioSciences Highlights PBGENE-DMD Program and Trial
- Precision BioSciences Advances PBGENE-DMD Trial, Putting New Focus on Duchenne Gene Therapy
- Precision BioSciences reports Q4 EPS $1.05, consensus (64c)
- Precision receives two notices of allowance from USPTO for PBGENE-HBV